Antibiotic resistance: Tools for effective translational research

Ploy, Marie-Cécile; Andremont, Antoine; Valtier, B.; Jeunne, Claire Le; Dumartin, C.; Guillemot, Didier; Bousquet‐mélou, Alain; Brun‐Buisson, Christian; Coignard, B.; Concordet, Didier; Couet, William; Bano, Joanie Del; Guilhaumou, Romain; Guyard, Cyril; Jouvin‐Marche, Evelyne; Kernéis, Solen; Khelifa, Mohamed Moncef Ben; Michaël, Mourez; Verdier, Marie‐Clémence

doi:10.1016/j.therap.2019.12.003

Cited by 5 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Third, 91% of studies had high ROB. This is consistent with findings from previous work and calls for significant improvements in the methods of AMS studies, building on professional recommendations and considering integration of implementation sciences aspects [27][28][29]. Fourth, when assessing interventions effectiveness, we focused on outcomes regarding antibiotic consumption and appropriateness; we did not consider other outcomes such as clinical results.…”

Section: Strengths and Limitationssupporting

confidence: 65%

Systematic review of factors promoting behaviour change toward antibiotic use in hospitals

Pouly¹,

Coppry²,

Rogues³

et al. 2022

Clinical Microbiology and Infection

Self Cite

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Strengths and Limitationssupporting

confidence: 65%

Systematic review of factors promoting behaviour change toward antibiotic use in hospitals

Pouly¹,

Coppry²,

Rogues³

et al. 2022

Clinical Microbiology and Infection

Self Cite

View full text Add to dashboard Cite

show abstract

“…Despite that quantitative models on how individual antibiotic use may impact AR at the population level are still absent, it is worth mentioning that a reduced antibiotic consumption has also begun to occur in a number of countries just as a result of a change in individual behavior (Edgar et al, 2009), and some tools and indicators to address these changes have been suggested (Ploy et al, 2020). The "tragedy of the commons" metaphor, first proposed in the XIX century (Lloyd, 1833) and later on discussed in 1968 (Hardin, 1968), has been used for addressing the sociology of AR, by showing how individual selfishness promotes antibiotic use, increases resistance, and influences the health of the community by impairing antibiotic efficacy (Baquero and Campos, 2003;Foster and Grundmann, 2006).…”

Section: Social Norms and Tipping Points In Antibiotic Resistance: A mentioning

confidence: 99%

Antibiotic Resistance: Moving From Individual Health Norms to Social Norms in One Health and Global Health

et al. 2020

View full text Add to dashboard Cite

Antibiotic resistance is a problem for human health, and consequently, its study had been traditionally focused toward its impact for the success of treating human infections in individual patients (individual health). Nevertheless, antibiotic-resistant bacteria and antibiotic resistance genes are not confined only to the infected patients. It is now generally accepted that the problem goes beyond humans, hospitals, or long-term facility settings and that it should be considered simultaneously in human-connected animals, farms, food, water, and natural ecosystems. In this regard, the health of humans, animals, and local antibiotic-resistance-polluted environments should influence the health of the whole interconnected local ecosystem (One Health). In addition, antibiotic resistance is also a global problem; any resistant microorganism (and its antibiotic resistance genes) could be distributed worldwide. Consequently, antibiotic resistance is a pandemic that requires Global Health solutions. Social norms, imposing individual and group behavior that favor global human health and in accordance with the increasingly collective awareness of the lack of human alienation from nature, will positively influence these solutions. In this regard, the problem of antibiotic resistance should be understood within the framework of socioeconomic and ecological efforts to ensure the sustainability of human development and the associated human-natural ecosystem interactions.

show abstract

“…Instead, regulators rely upon data regarding improved spectrum from both in vitro and in preclinical animal infection models. There are several reasons for this clinical trial design, particularly including patients infected with multi-drug resistant bacteria in a trial showing superiority will be too long and costly, and there is no standard treatment allowing an early inclusion and randomization [ 17 ]. Policymakers are frustrated that new antibiotics show no greater benefit than existing antibiotics.…”

Section: Resultsmentioning

confidence: 99%

National Facilitators and Barriers to the Implementation of Incentives for Antibiotic Access and Innovation

Årdal

Lacotte

Edwards³

et al. 2021

Antibiotics

Self Cite

View full text Add to dashboard Cite

Prominent reports have assessed the challenges to antibiotic innovation and recommended implementing “pull” incentives, i.e., mechanisms that give increased and predictable revenues for important, marketed antibiotics. We set out to understand countries’ perceptions of these recommendations, through frank and anonymous dialogue. In 2019 and 2020, we performed in-depth interviews with national policymakers and antibiotic resistance experts in 13 countries (ten European countries and three non-European) for a total of 73 individuals in 27 separate interviews. Interviewees expressed high-level support for antibiotic incentives in 11 of 13 countries. There is recognition that new economic incentives are needed to maintain a reliable supply to essential antibiotics. However, most countries are uncertain which incentives may be appropriate for their country, which antibiotics should be included, how to implement incentives, and how much it will cost. There is a preference for a multinational incentive, so long as it is independent of national pricing, procurement, and reimbursement processes. Nine countries indicated a preference for a model that ensures access to both existing and new antibiotics, with the highest priority for existing antibiotics. Twelve of thirteen countries indicated that shortages of existing antibiotics is a serious problem. Since countries are skeptical about the public health value of many recently approved antibiotics, there is a mismatch regarding revenue expectations between policymakers and antibiotic innovators. This paper presents important considerations for the design and implementation of antibiotic pull mechanisms. We also propose a multinational model that appears to match the needs of both countries and innovators.

show abstract

Antibiotic resistance: Tools for effective translational research

Cited by 5 publications

References 16 publications

Systematic review of factors promoting behaviour change toward antibiotic use in hospitals

Systematic review of factors promoting behaviour change toward antibiotic use in hospitals

Antibiotic Resistance: Moving From Individual Health Norms to Social Norms in One Health and Global Health

National Facilitators and Barriers to the Implementation of Incentives for Antibiotic Access and Innovation

Contact Info

Product

Resources

About